Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (641-650 of 713) with videos related to

Pageof 72
Sort By:
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Hematology & Oncology|January 7, 2022
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committeeJames L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell TransplantationBetül Oran, Antonio M Jimenez, Marcos De Lima, et al.
Blood|August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterYasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
Pageof 72

Showing results (641-650 of 713) with videos related to

Sort By:
Pageof 72
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
American Journal of Hematology|June 26, 2019
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenibFevzi Yalniz, Iman Abou Dalle, Hagop Kantarjian, et al.
Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.
Journal of Hematology & Oncology|January 7, 2022
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committeeJames L Januzzi, Joseph M Garasic, Scott E Kasner, et al.
Leukemia|June 19, 2019
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemiaSusan Branford, Dennis Dong Hwan Kim, Jane F Apperley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell TransplantationBetül Oran, Antonio M Jimenez, Marcos De Lima, et al.
Blood|August 27, 2005
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer CenterYasuhiro Oki, Hagop M Kantarjian, Xian Zhou, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
American Journal of Hematology|November 5, 2019
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survivalMusa Yilmaz, Hagop Kantarjian, Xuemei Wang, et al.
Pageof 72